美罗华联合CHOP治疗B细胞性非霍奇金淋巴瘤的临床研究

The clinical study of CHOP combined with Rituximab in treating B-cell non-Hodgkin lymphoma

目的评价美罗华(Rituximab)联合CHOP(R-CHOP)治疗CD20阳性B细胞性非霍奇金淋巴瘤(NHL)的临床疗效及不良反应。方法采用同期非随机对照的前瞻性研究方法,将62例初治B细胞淋巴瘤患者分为R-CHOP组和CHOP组。其中,R-CHOP组34例,采用R-CHOP方案化疗;CHOP组28例,采用CHOP方案化疗。6个疗程后比较两组的临床疗效及不良反应。结果R-CHOP组完全缓解率79.4%(27/34),总有效率91.2%(31/34);CHOP组完全缓解率57.1%(16/28),总有效率71.4%(20/28),两组临床疗效差异有统计学意义(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。结论R-CHOP方案治疗CD20阳性B细胞性非霍奇金淋巴瘤疗效更好,且未增加不良反应。

Objective To evaluate the efficacy and side-effects of CHOP combined with Rituximab（R-CHOP） in treating CD 20 positive B-cell non-Hodgkin lymphoma（NHL）.Methods Applying the prospective study method with non-random and concurrent control,62 newly diagnosed patients with B-cell NHL were divided into two groups,R-CHOP group and CHOP group.34 cases in R-CHOP group were treated with R-CHOP while 28 cases in CHOP group were treated with CHOP.The efficacy and side-effects of these two groups were evaluated after 6 courses of treatment.Results The complete remission（CR） rate and total effective rate in R-CHOP group were 79.4%（27/34） and 91.2%（31/34）,while the complete remission（CR） rate and total effective rate in CHOP group were 57.1%（16/28） and 71.4%（20/28）.The efficacy differences between the two groups had statistical significance（P0.05） while the side-effects differences between the two groups had no statistical significance（P0.05）.Conclusion Treating CD 20 positive B-cell NHL with R-CHOP is more effective,while there are no additional side-effects.